Congress funds rare kidney disease research targeting health disparities
H.R. 1518 — New Era of Preventing End-Stage Kidney Disease Act · Filed by Gus Bilirakis (R-FL) · 61 cosponsors · Introduced Feb 24, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill establishes federally funded research centers focused on rare kidney diseases, particularly glomerular diseases, and authorizes studies on early detection and treatment methods. It funds nephrology training programs to increase specialists serving underserved populations, and directs the Secretary of Health and Human Services to study diagnostic testing, treatment patterns, and public awareness strategies for rare kidney disease.
Why we flagged it
The bill's core mechanism is establishing research centers and funding clinical training in nephrology, with supporting studies on diagnostic and treatment methods. It is fundamentally a public health infrastructure and workforce development measure.
What the text implies
- The explicit prohibition on using quality-adjusted life years (QALYs) and disability-adjusted life years (DALYs) in cost-effectiveness assessments may signal a broader shift in how NIH-funded research evaluates treatments for rare diseases affecting disabled populations, potentially affecting future research prioritization across other conditions.
- Emphasis on APOL1 gene testing and genetic counseling access may create demand for genetic testing infrastructure and counselor training that currently lacks adequate reimbursement or workforce capacity.
The full analysis lists 3 implications of this text.
Who stands to gain
academic medical centers and research institutions; nephrology training programs; genetic testing and diagnostic companies